source
- Qiagen names Jonathan M. Pratt as new chief executive after nine-month searchQiagen announced that Jonathan M. Pratt will take over as chief executive, ending a nine‑month search for a successor. Pratt arrives from Filtration Group, where he served as president and CEO. He…
- TME Pharma narrows licensing talks for brain-cancer drug NOX-A12, eyes $1 billion marketTME Pharma, a German biotech, says it has narrowed potential partners for its experimental glioblastoma therapy NOX-A12, a CCL2 inhibitor, to two firms and entered a final evaluation phase. The co…